KR100711142B1 - 노인성 치매의 치료에 적합한 2,400 돌턴의 평균 분자량을갖는 글라이코자미노글리칸 - Google Patents

노인성 치매의 치료에 적합한 2,400 돌턴의 평균 분자량을갖는 글라이코자미노글리칸 Download PDF

Info

Publication number
KR100711142B1
KR100711142B1 KR1020017014505A KR20017014505A KR100711142B1 KR 100711142 B1 KR100711142 B1 KR 100711142B1 KR 1020017014505 A KR1020017014505 A KR 1020017014505A KR 20017014505 A KR20017014505 A KR 20017014505A KR 100711142 B1 KR100711142 B1 KR 100711142B1
Authority
KR
South Korea
Prior art keywords
molecular weight
daltons
treatment
glycosaminoglycan
average molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017014505A
Other languages
English (en)
Korean (ko)
Other versions
KR20020005033A (ko
Inventor
움베르토 코리넬리
데엠브로시루이기
하닌이스라엘
파리드자웨드
리존
로렌스스탠리
머비스로날드에프.
Original Assignee
움베르토 코리넬리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 움베르토 코리넬리 filed Critical 움베르토 코리넬리
Publication of KR20020005033A publication Critical patent/KR20020005033A/ko
Application granted granted Critical
Publication of KR100711142B1 publication Critical patent/KR100711142B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
KR1020017014505A 1999-05-14 2000-05-12 노인성 치매의 치료에 적합한 2,400 돌턴의 평균 분자량을갖는 글라이코자미노글리칸 Expired - Fee Related KR100711142B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI99A001066 1999-05-14
IT1999MI001066A IT1312107B1 (it) 1999-05-14 1999-05-14 Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile

Publications (2)

Publication Number Publication Date
KR20020005033A KR20020005033A (ko) 2002-01-16
KR100711142B1 true KR100711142B1 (ko) 2007-04-24

Family

ID=11382970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014505A Expired - Fee Related KR100711142B1 (ko) 1999-05-14 2000-05-12 노인성 치매의 치료에 적합한 2,400 돌턴의 평균 분자량을갖는 글라이코자미노글리칸

Country Status (22)

Country Link
US (1) US6979680B1 (enExample)
EP (1) EP1181024B1 (enExample)
JP (1) JP2002544233A (enExample)
KR (1) KR100711142B1 (enExample)
CN (1) CN1178667C (enExample)
AT (1) ATE288761T1 (enExample)
AU (1) AU764743C (enExample)
CA (1) CA2373975A1 (enExample)
CZ (1) CZ20014092A3 (enExample)
DE (1) DE60018061T2 (enExample)
DK (1) DK1181024T3 (enExample)
ES (1) ES2237425T3 (enExample)
HK (1) HK1039903B (enExample)
HU (1) HUP0201100A3 (enExample)
IL (1) IL146458A0 (enExample)
IT (1) IT1312107B1 (enExample)
NO (1) NO328902B1 (enExample)
PL (1) PL198016B1 (enExample)
PT (1) PT1181024E (enExample)
RU (1) RU2248800C2 (enExample)
WO (1) WO2000069444A1 (enExample)
ZA (1) ZA200109331B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344781A1 (en) * 2002-03-12 2003-09-17 Laboratori Derivati Organici S.P.A. Process for the depolymerization of glycosaminoglycanes and products obtained therefrom
ITMI20031023A1 (it) * 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
EP1524276A1 (en) * 2003-10-16 2005-04-20 Laboratori Derivati Organici S.P.A. Multistep process for the physical depolymerization of heparin and products obtained therefrom
US7939512B2 (en) 2004-10-13 2011-05-10 Laboratori Derivati Organici Spa Multistep process for the physical depolymerization of heparin and products obtained therefrom
DE602006016990D1 (de) 2005-12-22 2010-10-28 Bellus Health Int Ltd Behandlung von diabetischer nephropathie
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8896239B2 (en) 2008-05-22 2014-11-25 Vladimir Yegorovich Balakin Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system
CN102119586B (zh) 2008-05-22 2015-09-02 弗拉迪米尔·叶戈罗维奇·巴拉金 多场带电粒子癌症治疗方法和装置
JP5450602B2 (ja) 2008-05-22 2014-03-26 エゴロヴィチ バラキン、ウラジミール シンクロトロンによって加速された荷電粒子を用いて腫瘍を治療する腫瘍治療装置
EP2283713B1 (en) 2008-05-22 2018-03-28 Vladimir Yegorovich Balakin Multi-axis charged particle cancer therapy apparatus
US8841866B2 (en) 2008-05-22 2014-09-23 Vladimir Yegorovich Balakin Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system
SG173879A1 (en) 2009-03-04 2011-10-28 Protom Aozt Multi-field charged particle cancer therapy method and apparatus
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2675993T3 (es) * 2011-10-14 2018-07-16 Centre National De La Recherche Scientifique Procedimiento de diagnóstico, pronóstico o tratamiento de enfermedades neurodegenerativas
CN112426434A (zh) * 2020-11-04 2021-03-02 山东大学 硫酸乙酰肝素在防治阿尔兹海默症中的应用
CN114478816A (zh) * 2022-02-11 2022-05-13 上海兴糖生物技术有限公司 一种白玉蜗牛多糖及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243974B1 (en) * 1986-05-01 1994-03-02 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IT1240615B (it) * 1990-04-03 1993-12-17 Mediolanum Farmaceutici Spa Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation

Also Published As

Publication number Publication date
NO328902B1 (no) 2010-06-14
DE60018061D1 (de) 2005-03-17
EP1181024A1 (en) 2002-02-27
NO20015544D0 (no) 2001-11-13
CN1178667C (zh) 2004-12-08
HK1039903A1 (en) 2002-05-17
AU4405200A (en) 2000-12-05
HK1039903B (en) 2005-08-26
HUP0201100A2 (hu) 2002-07-29
AU764743B2 (en) 2003-08-28
AU764743C (en) 2004-03-18
CZ20014092A3 (cs) 2002-04-17
PL352070A1 (en) 2003-07-28
PT1181024E (pt) 2005-06-30
CA2373975A1 (en) 2000-11-23
IT1312107B1 (it) 2002-04-04
ATE288761T1 (de) 2005-02-15
ES2237425T3 (es) 2005-08-01
HUP0201100A3 (en) 2003-03-28
PL198016B1 (pl) 2008-05-30
NO20015544L (no) 2002-01-14
US6979680B1 (en) 2005-12-27
EP1181024B1 (en) 2005-02-09
DK1181024T3 (da) 2005-06-13
CN1350459A (zh) 2002-05-22
DE60018061T2 (de) 2006-04-13
ITMI991066A1 (it) 2000-11-14
KR20020005033A (ko) 2002-01-16
JP2002544233A (ja) 2002-12-24
ZA200109331B (en) 2002-08-28
RU2248800C2 (ru) 2005-03-27
IL146458A0 (en) 2002-07-25
WO2000069444A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
KR100711142B1 (ko) 노인성 치매의 치료에 적합한 2,400 돌턴의 평균 분자량을갖는 글라이코자미노글리칸
Plant et al. Inhibitory proteoglycan immunoreactivity is higher at the caudal than the rostral Schwann cell graft-transected spinal cord interface
Snow et al. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain
US5250519A (en) Non-anticoagulant heparin derivatives
JP6703806B2 (ja) 低抗凝固剤ヘパリン
Dusart et al. Late axonal sprouting of injured Purkinje cells and its temporal correlation with permissive changes in the glial scar
JPH04503950A (ja) 平滑筋細胞増殖のインヒビターとしてのヘパリン断片
US6573251B2 (en) Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
Walzer et al. Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology
DE3422518A1 (de) Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
JP4149545B2 (ja) 低分子量のフカン類とその医薬組成物
Rees et al. Is silica involved in neuritic (senile) plaque formation?
JPH10503168A (ja) 神経系の損傷の処置のための置換デキストランの使用ならびにヘパラン硫酸に富む分画
Smaoui et al. Gentamicin administered during gestation alters glomerular basement membrane development
JP2010534232A (ja) 組成物および治療
Hanin et al. C3, a promising ultra low molecular weight glycosaminoglycan for the treatment of Alzheimer’s disease
Hanin Lee, Stanley A. Lorens and Jawed Fareed
BLOCKADE AMYLOID (25-35) INDUCED NEUROPATHOLOGY
BRAIN LOCALIZATION OF BASIC FIBROBLAST GROWTH FACTOR (bFGF) AND HEPARAN SULFATE GLYCOSAMINOGLYCANS IN AGED BRAIN AND ALZHEIMER’S DISEASE
Krzywkowski Céline Morissette, Diane Lacombe, Xianqi Kong, Ahmed Aman, Pascale Krzywkowski, Lioudmila Rodionova, Mounia Azzi, Daniel Delorme, and Barry D. Greenberg

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100419

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100419